Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: We aimed to evaluate the correlation between serum calprotectin and clinical and ultrasonographic (US) variables in early-onset psoriatic arthritis (PsA) and controls with rheumatoid arthritis (RA). METHODS: In a retrospective cross-sectional study, including PsA and matched RA patients, 44 joint counts (TJC, SJC), calprotectin, ESR and CRP were measured. US of wrists and MCPs 1-5 was performed, with grey-scale (GS) and power Doppler (PD) scored 0-3 at each site, summed in a total score. The correlation between calprotectin, clinical and US variables was evaluated by Spearman's coefficient, the predictivity by calprotectin of US by regression. Secondary analyses separating polyarticular PsA and using different US definitions (GS>1, PD>1) were performed. RESULTS: 78 PsA and 78 RA were included (PsA male 32%; mean age 51.7 (13.5)). Calprotectin did not significantly differ in PsA and RA. In PsA, calprotectin correlated with GS score (ρ=0.340, p=0.008), PD score (ρ=0.292, p=0.023) and the presence of PD (ρ=0.263, p=0.042); in RA there were no significant correlations. In polyarticular PsA, a significant correlation between calprotectin and GS (ρ=0.369, p=0.019) and PD scores (ρ=0.363, p=0.021) was confirmed. In both PsA and RA, calprotectin and CRP significantly correlated, while SJC and TJC did not. In the regression analysis, calprotectin did not predict US variables in PsA. Similar results were achieved in RA. CONCLUSIONS: In early PsA, serum calprotectin correlates with US measures of disease activity. Our results provide preliminary evidence for the application of this biomarker in early PsA.
Original languageEnglish
Pages (from-to)429-436
Number of pages8
JournalClinical and Experimental Rheumatology
Volume37
Issue number3
Publication statusPublished - 2019

Fingerprint

Leukocyte L1 Antigen Complex
Psoriatic Arthritis
Synovitis
Rheumatoid Arthritis
Retrospective Studies
Cross-Sectional Studies
Serum
Wrist

Keywords

  • antirheumatic agent
  • biological marker
  • calgranulin
  • blood
  • cross-sectional study
  • female
  • human
  • male
  • middle aged
  • psoriatic arthritis
  • retrospective study
  • rheumatoid arthritis
  • synovitis
  • Antirheumatic Agents
  • Arthritis, Psoriatic
  • Arthritis, Rheumatoid
  • Biomarkers
  • Cross-Sectional Studies
  • Female
  • Humans
  • Leukocyte L1 Antigen Complex
  • Male
  • Middle Aged
  • Retrospective Studies
  • Synovitis

Cite this

@article{375f32831e734c2ca7f4a6a93338baf3,
title = "Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study",
abstract = "OBJECTIVES: We aimed to evaluate the correlation between serum calprotectin and clinical and ultrasonographic (US) variables in early-onset psoriatic arthritis (PsA) and controls with rheumatoid arthritis (RA). METHODS: In a retrospective cross-sectional study, including PsA and matched RA patients, 44 joint counts (TJC, SJC), calprotectin, ESR and CRP were measured. US of wrists and MCPs 1-5 was performed, with grey-scale (GS) and power Doppler (PD) scored 0-3 at each site, summed in a total score. The correlation between calprotectin, clinical and US variables was evaluated by Spearman's coefficient, the predictivity by calprotectin of US by regression. Secondary analyses separating polyarticular PsA and using different US definitions (GS>1, PD>1) were performed. RESULTS: 78 PsA and 78 RA were included (PsA male 32{\%}; mean age 51.7 (13.5)). Calprotectin did not significantly differ in PsA and RA. In PsA, calprotectin correlated with GS score (ρ=0.340, p=0.008), PD score (ρ=0.292, p=0.023) and the presence of PD (ρ=0.263, p=0.042); in RA there were no significant correlations. In polyarticular PsA, a significant correlation between calprotectin and GS (ρ=0.369, p=0.019) and PD scores (ρ=0.363, p=0.021) was confirmed. In both PsA and RA, calprotectin and CRP significantly correlated, while SJC and TJC did not. In the regression analysis, calprotectin did not predict US variables in PsA. Similar results were achieved in RA. CONCLUSIONS: In early PsA, serum calprotectin correlates with US measures of disease activity. Our results provide preliminary evidence for the application of this biomarker in early PsA.",
keywords = "antirheumatic agent, biological marker, calgranulin, blood, cross-sectional study, female, human, male, middle aged, psoriatic arthritis, retrospective study, rheumatoid arthritis, synovitis, Antirheumatic Agents, Arthritis, Psoriatic, Arthritis, Rheumatoid, Biomarkers, Cross-Sectional Studies, Female, Humans, Leukocyte L1 Antigen Complex, Male, Middle Aged, Retrospective Studies, Synovitis",
author = "G. Sakellariou and G. Lombardi and B. Vitolo and M. Gomarasca and M. Faraldi and R. Caporali and G. Banfi and C. Montecucco",
note = "Export Date: 10 October 2019 Chemicals/CAS: Antirheumatic Agents; Biomarkers; Leukocyte L1 Antigen Complex",
year = "2019",
language = "English",
volume = "37",
pages = "429--436",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",

}

TY - JOUR

T1 - Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study

AU - Sakellariou, G.

AU - Lombardi, G.

AU - Vitolo, B.

AU - Gomarasca, M.

AU - Faraldi, M.

AU - Caporali, R.

AU - Banfi, G.

AU - Montecucco, C.

N1 - Export Date: 10 October 2019 Chemicals/CAS: Antirheumatic Agents; Biomarkers; Leukocyte L1 Antigen Complex

PY - 2019

Y1 - 2019

N2 - OBJECTIVES: We aimed to evaluate the correlation between serum calprotectin and clinical and ultrasonographic (US) variables in early-onset psoriatic arthritis (PsA) and controls with rheumatoid arthritis (RA). METHODS: In a retrospective cross-sectional study, including PsA and matched RA patients, 44 joint counts (TJC, SJC), calprotectin, ESR and CRP were measured. US of wrists and MCPs 1-5 was performed, with grey-scale (GS) and power Doppler (PD) scored 0-3 at each site, summed in a total score. The correlation between calprotectin, clinical and US variables was evaluated by Spearman's coefficient, the predictivity by calprotectin of US by regression. Secondary analyses separating polyarticular PsA and using different US definitions (GS>1, PD>1) were performed. RESULTS: 78 PsA and 78 RA were included (PsA male 32%; mean age 51.7 (13.5)). Calprotectin did not significantly differ in PsA and RA. In PsA, calprotectin correlated with GS score (ρ=0.340, p=0.008), PD score (ρ=0.292, p=0.023) and the presence of PD (ρ=0.263, p=0.042); in RA there were no significant correlations. In polyarticular PsA, a significant correlation between calprotectin and GS (ρ=0.369, p=0.019) and PD scores (ρ=0.363, p=0.021) was confirmed. In both PsA and RA, calprotectin and CRP significantly correlated, while SJC and TJC did not. In the regression analysis, calprotectin did not predict US variables in PsA. Similar results were achieved in RA. CONCLUSIONS: In early PsA, serum calprotectin correlates with US measures of disease activity. Our results provide preliminary evidence for the application of this biomarker in early PsA.

AB - OBJECTIVES: We aimed to evaluate the correlation between serum calprotectin and clinical and ultrasonographic (US) variables in early-onset psoriatic arthritis (PsA) and controls with rheumatoid arthritis (RA). METHODS: In a retrospective cross-sectional study, including PsA and matched RA patients, 44 joint counts (TJC, SJC), calprotectin, ESR and CRP were measured. US of wrists and MCPs 1-5 was performed, with grey-scale (GS) and power Doppler (PD) scored 0-3 at each site, summed in a total score. The correlation between calprotectin, clinical and US variables was evaluated by Spearman's coefficient, the predictivity by calprotectin of US by regression. Secondary analyses separating polyarticular PsA and using different US definitions (GS>1, PD>1) were performed. RESULTS: 78 PsA and 78 RA were included (PsA male 32%; mean age 51.7 (13.5)). Calprotectin did not significantly differ in PsA and RA. In PsA, calprotectin correlated with GS score (ρ=0.340, p=0.008), PD score (ρ=0.292, p=0.023) and the presence of PD (ρ=0.263, p=0.042); in RA there were no significant correlations. In polyarticular PsA, a significant correlation between calprotectin and GS (ρ=0.369, p=0.019) and PD scores (ρ=0.363, p=0.021) was confirmed. In both PsA and RA, calprotectin and CRP significantly correlated, while SJC and TJC did not. In the regression analysis, calprotectin did not predict US variables in PsA. Similar results were achieved in RA. CONCLUSIONS: In early PsA, serum calprotectin correlates with US measures of disease activity. Our results provide preliminary evidence for the application of this biomarker in early PsA.

KW - antirheumatic agent

KW - biological marker

KW - calgranulin

KW - blood

KW - cross-sectional study

KW - female

KW - human

KW - male

KW - middle aged

KW - psoriatic arthritis

KW - retrospective study

KW - rheumatoid arthritis

KW - synovitis

KW - Antirheumatic Agents

KW - Arthritis, Psoriatic

KW - Arthritis, Rheumatoid

KW - Biomarkers

KW - Cross-Sectional Studies

KW - Female

KW - Humans

KW - Leukocyte L1 Antigen Complex

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Synovitis

M3 - Article

VL - 37

SP - 429

EP - 436

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -